(Q37999682)

26 August 2017

title

Advances in the follow-up of differentiated or medullary thyroid cancer (English)

1 reference

26 August 2017

1

Rossella Elisei

1 reference

26 August 2017

Aldo Pinchera

2

1 reference

26 August 2017

publication date

3 April 2012

1 reference

Nature Reviews Endocrinology

26 August 2017

published in

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

8

1 reference

26 August 2017

page(s)

466-475

1 reference

Papillary and follicular thyroid carcinoma

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, Massachusetts area: A retrospective chart review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Medullary thyroid cancer: management guidelines of the American Thyroid Association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

The British Thyroid Association guidelines for the management of thyroid cancer in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Thyroid nodule guidelines: agreement, disagreement and need for future research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

A sensitive Tg assay or rhTSH stimulated Tg: what's the best in the long-term follow-up of patients with differentiated thyroid carcinoma?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Pulmonary fibrosis following radioiodine therapy of pulmonary metastases from differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Targeted therapies for thyroid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Pentagastrin, Calcium and Whisky Stimulated Serum Calcitonin in Medullary Carcinoma of the Thyroid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Discovery of a new broad resonance in 19Ne: implications for the destruction of the cosmic gamma-ray emitter 18F

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

DNA extraction from formalin-fixed, paraffin-embedded tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Medullary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Development of a sensitive and specific quantitative reverse transcription-polymerase chain reaction assay for blood thyroglobulin messenger ribonucleic acid in the follow-up of patients with differentiated thyroid carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.38

MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?

31 March 2020

1 reference

12 December 2020

Recombinant human thyroid-stimulating hormone (rhTSH): clinical development

1 reference

12 December 2020

Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy

1 reference

12 December 2020

Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer

1 reference

12 December 2020

Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels

1 reference

12 December 2020

Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan

1 reference

12 December 2020

Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma

1 reference

12 December 2020

The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC).

1 reference

12 December 2020

Detection of recurrent thyroid cancer by sensitive nested reverse transcription-polymerase chain reaction of thyroglobulin and sodium/iodide symporter messenger ribonucleic acid transcripts in peripheral blood

1 reference

12 December 2020

The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2012.38

1 reference

26 August 2017

1 reference